INNOCARE - Announcement of Board of Directors Resolutions
InnoCare Pharma Limited
Nuocheng Jianhua Pharmaceutical Co., Ltd.
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9969)
Overseas regulatory announcement
This announcement is made by InnoCare Pharmaceuticals Limited (the "Company") in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
This is to set forth the "Announcement on Board Resolutions" published by the company on the website of the Shanghai Stock Exchange, "Announcement on the Third Vesting Period of the First Granted Part and the Second Vesting Period of the Reserved Granted Part of the 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan", and "Announcement on the Voiding of the Partially Granted Restricted Stocks that have not yet vested" Announcement", "Announcement on the use of idle self-owned funds for cash management", "Self-examination report on insiders' buying and selling of company stocks under the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan", "List of first-time incentive recipients of the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan (as of the first grant date)", "Verification Opinions of the Remuneration Committee of the Board of Directors on the Third Vesting Period of the Initial Grant Part of the Science and Technology Innovation Board Restricted Stock Incentive Plan in 2023 and the List of Vesting Parties in the Second Vesting Period of the Reserved Grant Part", "Verification Opinions of the Board of Directors Remuneration Committee on the List of Incentive Objects of the First Grant of the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan", "Shanghai Fangda Law Firm on InnoCare Pharma Limited)'s 2025 Annual General Meeting of Shareholders", "Shanghai Fangda Law Firm's Legal Opinion on InnoCare Pharma Limited's 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan's 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan's First Grant Part's Third Vesting Period and Reserved Grant Part's Second Vesting Period Attribution Conditions Achievements and Certain Restricted Stock Invalidation Related Matters" and "Shanghai Fangda Law Firm's Legal Opinion on InnoCare Pharma Limited's 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan" Limited) Legal Opinion on Matters Related to the First Grant of the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan".
By order of the board of directors
Nuocheng Jianhua Pharmaceutical Co., Ltd.
Chairman and Executive Director
Dr. Cui Jisong
Hong Kong, June 16, 2026
As of the date of this announcement, the board of directors includes Dr. Cui Jisong, the chairman and executive director; Dr. Zhao Renbin, the executive director; Dr. Shi Yigong and Mr. Xie Ronggang, the non-executive directors; and Ms. Hu Lan, Dr. Dong Dandan and Professor Guan Kunliang, the independent non-executive directors.
Remuneration Committee of the Board of Directors of InnoCheng Jianhua Pharmaceutical Co., Ltd.
About the Science and Technology Innovation Board Restricted Stock Incentive Plan
2023
Verification opinions on the vesting list for the third vesting period of the initial grant portion and the second vesting period of the reserved grant portion
The Remuneration Committee of the Board of Directors of Innocent Jianhua Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") complies with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Measures for the Administration of Equity Incentives of Listed Companies (hereinafter referred to as the "Administration Measures"), the Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules (hereinafter referred to as the "Listing Rules"), and the "Self-Regulatory Supervision Guidelines for Companies Listed on the Science and Technology Innovation Board". No. 4 - Equity Incentive Information Disclosure" and other relevant laws, regulations and normative documents, the list of incentive objects that meet the vesting conditions for the third vesting period of the first grant part of this restricted stock incentive plan and the second vesting period of the reserved grant part of this restricted stock incentive plan has been verified. After verification, it is believed that: 134 are intended to be vested this time. The incentive object shall meet the incentive object conditions stipulated in the "Administrative Measures", "Listing Rules" and other laws, regulations and normative documents, comply with the scope of incentive objects specified in this incentive plan, and its qualification as an incentive object of the company's incentive plan is legal and valid. The vesting conditions for the third vesting period of the first grant portion and the second vesting period of the reserved grant portion of this incentive plan have been met. Therefore, the remuneration committee of the board of directors agreed to this vesting list.
(No text below)
Remuneration Committee of the Board of Directors of InnoCheng Jianhua Pharmaceutical Co., Ltd.
June 16, 2026